The Peptide Ban Is Ending: FDA Officially Begins Reclassification Process for BPC-157, TB-500 & More

تفصیل

Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice and scheduling a July 2026 Pharmacy Compounding Advisory Committee meeting. This episode breaks down the full regulatory timeline, what the Category 1 vs Category 2 framework means, what today's action specifically does, and what patients and clinicians should know right now. Clinical, evidence-grounded, no hype.